GNPX
Genprex, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.24
−3.03%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$2.35
From 52W high−98.26%
Volume201443.00
Market cap$1.84M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$2.35
From 52W high
−98.26%
Volume
201443.00
Market cap
$1.84M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.8x
P/E (TTM)
—
RSI (14)
41.5
MomentumView details →
1D Return
−3.03%
YTD Return
−94.25%
SummaryUpdated Jun 1, 2026
Genprex, Inc. (NASDAQ:GNPX) is a clinical-stage biotechnology company founded in 2009 and headquartered in Austin, Texas. The company went public in March 2018 and focuses on developing innovative gene therapies for patients suffering from cancer and diabetes. As a clinical-stage company, Genprex does not yet generate meaningful revenue from product sales but instead relies on raising capital to fund its research and development activities as it advances its therapeutic candidates through various stages of clinical trials.
Similar companies
Latest newsMore news →
Genprex announced research finding that low TROP2 expression was associated with resistance to its REQORSA gene therapy across multiple preclinical models of non-small cell lung cancer.5h agoGenprex announced that research conducted under its sponsored collaboration with Meharry Medical College will be featured at the The Gerontological Society of America 2026 Annual Scientific Meeting on November 4–7, 2026.7d ago